Search Tag: anticoagulants

ICU Management

Reversal-of-direct-oral-anticoagulants

2021 23 Nov

This review focuses on different techniques to reverse direct oral anticoagulants,  either with specific or non-specific agents. D irect oral anticoagulants (DOACs) are now standing for Vitamin K antagonists in many clinical settings. They are recognised as a major step forward for our patients. Their efficacy has been confirmed...Read more

ICU Management

Treatment-options-for-factor-xa-inhibitor-related-bleeding

2019 26 Sep

Specific treatment options for factor Xa inhibitor-related bleeding, focusing on drugs like rivaroxaban, apixaban, and edoxaban.   Non-vitamin K oral anticoagulants (NOACs/DOACs) are direct reversible inhibitors of factor Xa. These drugs are also reversible inhibitors versus warfarin or other vitamin K antagonist that are used in Europe. Anticoagulants...Read more

ICU Management

Are-newer-anticoagulants-safer-than-warfarin

2018 03 Apr

A new study compared outcomes among patients with atrial fibrillation hospitalised for bleeding after starting anticoagulation (warfarin, dabigatran, or rivaroxaban). Results show rivaroxaban and dabigatran were associated with shorter hospitalisations; however, there were no differences in 30- and 90-day mortality. These findings suggest bleeding...Read more

ICU Management

Canadian-guidelines-on-dvt-released

2015 01 Oct

A panel of experts (InterEPID) has released a new Canadian guideline for the diagnosis and management of blood clots, specifically iliofemoral deep vein thrombosis (DVT), in the groin and thigh. The guideline, published in CMAJ (Canadian Medical Association Journal), was developed by a team of haematologists, vascular surgeons, interventional radiologists,...Read more

Cardiology Management

Consensus-paper-on-patient-preferences-for-arrhythmias-management

2015 25 Jun

A unique consensus paper on patient preferences for arrhythmias management was presented at EHRA EUROPACE – CARDIOSTIM 2015 and published in EP Europace. “Patients live with the consequences of treatments so it’s reasonable that they should have some say.” The document was produced by the European Heart Rhythm Association (EHRA), a registered branch...Read more

Cardiology Management

Fondaparinux-versus-heparin-lower-risk-of-bleeding-and-death

2015 17 Feb

According to a study published in JAMA, patients who receive fondaparinux after a certain type of heart attack had a lower risk of major bleeding events and death in the hospital and after six months as compared to patients who received low molecular weight heparin (LMWH). Both groups of patients had similar rates of subsequent heart attack or stroke....Read more

Cardiology Management

Venous-thromboembolism-treatments-compared

2014 16 Sep

According to a study published in JAMA, there is no significant difference in the clinical and safety outcomes associated with most treatment strategies for venous thromboembolism, a common medical condition manifested as deep vein thrombosis or pulmonary embolism. Venous thromboembolism is the third leading cause of cardiovascular death....Read more